8.36
-0.18 (-2.11%)
| Penutupan Terdahulu | 8.54 |
| Jumlah Dagangan | 675,827 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.63 |
| Harga / Jualan (P/S) | 8.54 |
| Harga / Buku (P/B) | 1.55 |
| Julat 52 Minggu |
| Margin Keuntungan | -79.94% |
| Margin Operasi (TTM) | -2,318.99% |
| EPS Cair (TTM) | -2.05 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5,556.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.33% |
| Nisbah Semasa (MRQ) | 9.00 |
| Aliran Tunai Operasi (OCF TTM) | -130.36 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -35.38 M |
| Pulangan Atas Aset (ROA TTM) | -15.49% |
| Pulangan Atas Ekuiti (ROE TTM) | -23.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Prothena Corporation plc | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | 4.0 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.13 |
|
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 18.99% |
| % Dimiliki oleh Institusi | 74.34% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| SCULLY WILLIAM P | 8.75 | - | 265,500 | 2,324,880 |
| Jumlah Keseluruhan Kuantiti Bersih | 265,500 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 2,324,880 | |||
| Purata Pembelian Keseluruhan ($) | 8.75 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| SCULLY WILLIAM P | 29 Sep 2026 | Beli (+) | 162,000 | 8.78 | 1,422,360 | |
| SCULLY WILLIAM P | 28 Sep 2026 | Beli (+) | 103,500 | 8.72 | 902,520 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |